Stericycle study exposes prescription drug sharing and disposal habits

A majority of Americans (75%) believe that people sharing or selling their unused prescriptions, including opioids, is contributing to the growth of the opioid epidemic. 72% believe having a safe and secure way to dispose of leftover/unused prescription drugs would help combat the opioid epidemic, but the majority (71%) of Americans surveyed said their pharmacist, doctor or prescribing medical professional does not inform them of drug disposal methods. Read More →

Read More
Brea Neri
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation

There is high‐certainty evidence that using combination nicotine replacement therapy (NRT) versus single‐form NRT, and 4 mg versus 2 mg nicotine gum, can increase the chances of successfully stopping smoking. Twenty‐one mg patches resulted in higher quit rates than 14 mg (24‐hour) patches. Using a fast‐acting form of NRT, such as gum or lozenge, resulted in similar quit rates to nicotine patches. Read More →

Read More
Brea Neri
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Annals of Internal Medicine – Recent study aimed to determine optimal long-term osteoporosis drug treatment. Long-term alendronate and zoledronic acid therapies reduce fracture risk in women with osteoporosis. Long-term bisphosphonate treatment may increase risk for rare adverse events, and continuing treatment beyond 3 to 5 years may reduce risk for vertebral fractures. Long-term hormone therapy reduces hip fracture risks but has serious harms. Read More →

Read More
Brea Neri
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study

Annals of Internal Medicine - The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. The mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% in the metformin group, 3.7% in the ILS group, and 2.8% in the placebo group. Read More →

Read More
Brea Neri
FDA approves first generic naloxone nasal spray to treat opioid overdose

FDA - granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose. Naloxone nasal spray does not require assembly. This product can be used for adults or children and is easily administered by anyone, even those without medical training. The drug is sprayed into one nostril while the patient is lying on his or her back and can be repeated if necessary. Read More →

Read More
Brea Neri
FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines

FDA - advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. These behaviors appear to be more common with eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist). The FDA is requiring a Boxed Warning as well as a Contraindication to avoid use in patients who have previously experienced an episode of complex sleep behavior with eszopiclone, zaleplon, and zolpidem. Read More →

Read More
Brea Neri
Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-Analysis

Current evidence supports both efficacy and superiority of combination intranasal azelastine and fluticasone in reducing patient-reported symptom scores in patients with allergic rhinitis compared to monotherapy. Combination nasal spray should be considered as second-line therapy in patients with allergic rhinitis that is not controlled with monotherapy. Read More →

Read More
Brea Neri
CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study

BMJ - The risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with other risk factors for type 2 diabetes. Read More →

Read More
Brea Neri
Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis

AJPM - Tradeoffs exist between efforts to increase influenza vaccine uptake, including early season vaccination, and potential decreased vaccine effectiveness if protection wanes during influenza season. Older adults waiting until October to receive the flu vaccination could decrease waning vaccine effectiveness and decrease overall influenza cases as long as waiting does not result in decreased likelihood of receiving the vaccine. Read More →

Read More
Brea Neri
FDA approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of fracture

FDA approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of fracture. One dose of Evenity consists of two injections, one immediately following the other, given once a month by a health care professional. The bone forming effect of Evenity wanes after 12 doses so more than 12 doses should not be used. If osteoporosis therapy is needed after the 12 doses, patients should begin an osteoporosis treatment that reduces bone breakdown. Read More →

Read More
Brea Neri
CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain

CDC issued clarification that their Guideline for Prescribing Opioids for Chronic Pain was developed to provide recommendations for primary care clinicians who prescribe opioids for patients with chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline is not intended to deny clinically-appropriate opioid therapy to any patients who suffer acute or chronic pain from conditions such as cancer and sickle cell disease. Read More →

Read More
Brea Neri